|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Cash flows from operating activities | |||||
| Net income including non-controlling interests | |||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||
| Depreciation and amortization | |||||
| Bad debt expense | |||||
| Stock-based compensation | |||||
| Loss from sale of investments | |||||
| Gain on business divestitures | |||||
| Deferred income taxes | |||||
| Accretion of discounts on marketable debt securities, net | |||||
| Impairments of goodwill, long-lived assets and other assets | |||||
| Impairment of equity method investment | |||||
| Loss (income) from equity method investments, net | |||||
| Unrealized (gain) loss on debt and equity securities, net | |||||
| Revaluation of MLU B.V. call option | |||||
| Unrealized foreign currency transactions | |||||
| Other | |||||
| Change in assets and liabilities, net of impact of business acquisitions and disposals: | |||||
| Accounts receivable | |||||
| Prepaid expenses and other assets | |||||
| Collateral held by insurer | |||||
| Operating lease right-of-use assets | |||||
| Accounts payable | |||||
| Accrued insurance reserves | |||||
| Accrued expenses and other liabilities | |||||
| Operating lease liabilities | |||||
| Net cash provided by operating activities | |||||
| Cash flows from investing activities | |||||
| Purchases of property and equipment | |||||
| Purchases of non-marketable equity securities | |||||
| Purchases of marketable securities | |||||
| Proceeds from sale of non-marketable equity securities | |||||
| Proceeds from maturities and sales of marketable securities | |||||
| Proceeds from sale of equity method investments | |||||
| Proceeds from business divestiture | |||||
| Acquisition of businesses, net of cash acquired | |||||
| Purchase of notes receivables | |||||
| Other investing activities | |||||
| Net cash used in investing activities | |||||
| Cash flows from financing activities | |||||
| Proceeds from issuance and sale of subsidiary stock units | |||||
| Issuance of term loan and notes, net of issuance costs | |||||
| Purchase of Capped Calls | |||||
| Principal repayment on term loan and notes | |||||
| Principal repayment on Careem Notes | |||||
| Principal payments on finance leases | |||||
| Proceeds from the issuance of common stock under the Employee Stock Purchase Plan | |||||
| Repurchases of common stock | |||||
| Redemption of non-controlling interests | |||||
| Other financing activities | |||||
| Net cash used in financing activities | |||||
| Effect of exchange rate changes on cash and cash equivalents, and restricted cash and cash equivalents | |||||
| Net increase in cash and cash equivalents, and restricted cash and cash equivalents | |||||
| Cash and cash equivalents, and restricted cash and cash equivalents | |||||
| Reclassification from (to) assets held for sale during the period | |||||
| Beginning of period | |||||
| End of period | |||||
| Supplemental disclosures of cash flow information | |||||
| Cash paid for: | |||||
| Interest, net of amount capitalized | |||||
| Income taxes, net of refunds | |||||
| Non-cash investing and financing activities: | |||||
| Finance lease obligations | |||||
| Right-of-use assets obtained in exchange for lease obligations | |||||
| Common stock issued in connection with acquisitions | |||||
| Ownership interest received in exchange for divestitures | |||||
| Conversion of convertible notes to common stock related to Careem | |||||
Loading...